Physician profile
Luke C Bi
NPI 1700964202
$84,700.71
in general payments reported to CMS, 2019-2025
22 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $11K · 2021: $18K · 2022: $18K · 2023: $5,011 · 2024: $3,992 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,825 · Food and Beverage: $1,083 · Travel and Lodging: $445 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,825.00 |
| Food and Beverage | $1,083.37 |
| Travel and Lodging | $445.28 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,321.30 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $522.77 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $471.17 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $253.35 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.36 | 2020-2022 | |
| Gilead Sciences, INC. | $132.14 | 2019-2023 | |
| Braintree Laboratories, INC. | $108.37 | 2019-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $90.48 | 2019-2020 | |
| Abbott Laboratories | $89.93 | 2024-2025 | Alinity |
| Madrigal Pharmaceuticals | $79.96 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $66.01 | 2022-2025 | Ocaliva |
| Cook Medical LLC | $55.34 | 2020 | |
| Olympus America INC. | $42.25 | 2019-2024 | Visiglide |
| Organon LLC | $39.05 | 2021-2022 | |
| Shionogi INC | $38.83 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $28.61 | 2024 | Vegzelma |
| Portola Pharmaceuticals, LLC | $25.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.19 | 2019 | |
| Exact Sciences Corporation | $21.32 | 2025 | Cologuard Collection Kit |
| Conmed Corporation | $18.65 | 2025 | Conmed Biliary, Conmed Hemostasis |
| Covidien LP | $17.73 | 2019 | |
| Ucb, INC. | $16.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Bi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.